# US 2005/0033066 A1 · Pkb-3564 substance with neovascularization inhibitory activity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2005/0033066 A1
- Document ID: US20050033066A1
- Status: Published application
- Kind: A1
- Application number: 10/475,804
- Filed: 2002-04-24
- Published: 2005-02-10
- Earliest claimed: 2001-04-25
- Assignees: Riken; Institute of Biotechnology Applied to Soil Eumycetes
- Inventors: Hiroyuki Osada; Hideaki Kakeya; Hiroshi Konno; Susumu Kanazawa
- Web page: https://patentgrep.com/patent/US20050033066A1

## CPC

- C07D 493/22: in which the condensed system contains four or more hetero rings
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 13/12: of the kidneys
- A61P 17/14: for baldness or alopecia
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/20: for DNA viruses
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A compound represented by formula (I) wherein R1 represents hydrogen atom and R2 represents hydroxyl group, or R1 and R2 may combine together to represent oxo group or oxime group; R3 represents hydrogen atom and R4 represents hydroxyl group, or R3 and R4 may combine together to represent oxo group or oxime group; R5 represents hydrogen atom and R6 represents hydroxyl group, or R5 and R6 may combine together to represent oxo group or oxime group; R7 represents hydrogen atom and R8 represents hydrogen atom, or R7 and R8 may combine together to represent oxo group or oxime group; R9 and R10 represent hydrogen atom, an alkyl group, or an alkenyl group. The compound is useful as an active ingredient of a medicament having angiogenesis suppressive activity, apoptosis suppressive activity, and cell cycle inhibitory activity.

## Claims

### Claim 1

A compound represented by the general formula (I):
wherein R1 represents hydrogen atom and R2 represents hydroxyl group, or R1 and R2 may combine together to represent oxo group or oxime group; R3 represents hydrogen atom and R4 represents hydroxyl group, or R3 and R4 may combine together to represent oxo group or oxime group; R5 represents hydrogen atom and R6 represents hydroxyl group, or R5 and R6 may combine together to represent oxo group or oxime group; R7 represents hydrogen atom and R8 represents hydrogen atom, or R7 and R8 may combine together to represent oxo group or oxime group; and R9 and R10 independently represent hydrogen atom, an optionally substituted alkyl group, or an optionally substituted alkenyl group.

### Claim 2 (depends on 1)

The compound according to claim 1, wherein R1 is hydrogen atom, R2 is hydroxyl group, R3 and R4 combine together to represent oxo group, R5 is hydrogen atom, R6 is hydroxyl group, R7 and R8 combine together to represent oxo group, and R9 and R10 are both methyl groups.

### Claim 3 (depends on 1)

The compound according to claim 1, wherein R1 and R2 combine together to represent oxo group, R3 and R4 combine together to represent oxo group, R5 and R6 combine together to represent oxo group, R7 and R8 combine together to represent oxo group, and R9 and R10 are both methyl groups.

### Claim 4

A compound represented by the general formula (II):
wherein R11 represents hydrogen atom and R12 represents hydroxyl group, or R11 and R12 may combine together to represent oxo group or oxime group; R13 represents hydrogen atom and R14 represents hydroxyl group, or R13 and R14 may combine together to represent oxo group or oxime group; R15 represents hydrogen atom and R16 represents hydroxyl group, or R15 and R16 may combine together to represent oxo group or oxime group; R17 represents hydrogen atom and R18 represents hydrogen atom, or R17 and R18 may combine together to represent oxo group or oxime group; and R19 and R20 independently represent hydrogen atom, an optionally substituted alkyl group, or an optionally substituted alkenyl group.

### Claim 5 (depends on 4)

The compound according to claim 4, wherein R11 is hydrogen atom, R12 is hydroxyl group, R13 and R14 combine together to represent oxo group, R15 is hydrogen atom, R16 is hydroxyl group, R17 and R18 combine together to represent oxo group, and R19 and R20 are both methyl groups.

### Claim 6 (depends on 1, 2, 3, 4, 5)

A medicament which comprises the compound according to any one of claims 1 to 5 as an active ingredient.

### Claim 7 (depends on 6)

The medicament according to claim 6, which is an angiogenesis inhibitor.

### Claim 8 (depends on 6)

The medicament according to claim 6, which is an apoptosis suppressant.

### Claim 9 (depends on 6)

The medicament according to claim 6, which is a cell cycle inhibitor.

### Claim 10 (depends on 6)

The medicament according to claim 6, which is an antitumor agent.

### Claim 11 (depends on 6)

The medicament according to claim 6, which is used for preventive and/or therapeutic treatment of a disease in which abnormal acceleration of apoptosis is involved.
